“Voici un article de l’EHJ présentant des recommandations pour la prise en charge des syndromes coronariens aigus à l’ère du COVID-19.” présenté par le Dr Marie MOITRY
ANALYSE:Commentateur : Dr David REY. “Voici une étude américaine (New York) du COVID-19 chez des transplantés cardiaques.”
ABSTRACT :Aims/hypothesis Coronavirus disease-2019 (COVID-19) is a life-threatening infection caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) virus. Diabetes has rapidly emerged as a major comorbidity for COVID-19 severity. However, the phenotypic characteristics of diabetes in COVID-19 patients are unknown.
Source : AHA
Auteur : Naveed Sattar and al.
The Coronavirus Disease 2019 (COVID-19) pandemic has led to worldwide research efforts to identify people at greatest risk of developing critical illness and dying. Initial data pointed towards older individuals being particularly vulnerable, as well as those with diabetes or cardiovascular (including hypertension), respiratory or kidney disease. These problems are often concentrated in certain racial groups (e.g. African Americans and Asians) which also appear to be more prone to worse COVID-19 outcomes.
Source : ORCID
Auteur : Austin R. Morrison and al.
Letter to the Editor :
“Une « Letter to the Editor » concernant 2 patients avec forme respiratoire sévère de Covid chez qui l’utilisation de Tocilizumab s’est accompagnée d’une Hypertriglycéridémie majeure. Donc surveillance métabolique rigoureuse à prévoir dans cette indication.” proposé par le Dr Laurent MEYER.
Tocilizumab is an interleukin-6 (IL-6) receptor antibody and is progressing as a viable and promising treatment option in patients with severe coronavirus disease 2019 (COVID-19). IL-6 is known to have both immunomodulatory and metabolic actions. In this letter we outline two cases of acute hypertriglyceridemia in patients with COVID-19 treated with tocilizumab: one with elevated biomarkers consistent with acute pancreatitis the other without. Given the paucity of robust clinical trial data for most COVID-19 pharmacotherapies at this time, clinicians should continue to remain steadfast in recognition of interventions that improve clinical outcomes and vigilant in monitoring for acute adverse effects that are difficult to detect in clinical trials with small sample sizes. The observations from our two cases highlight the complex, not fully elucidated interrelationship between elevated IL-6 and pharmacologic interventions impacting this pathway. Clinicians should consider monitoring for hypertriglyceridemia and acute pancreatitis as described with chronic tocilizumab use for rheumatoid arthritis in those receiving it for COVID-19.
Source : JAMA Network
Auteur : Rita Rubin
Suzanne Watnick, MD, got the call at 9PM Friday, February 28. Aman in his 50s who received dialysis treatments at a Northwest Kidney Centers facility in Seattle was the first person with coronavirus disease 2019 (COVID-19) to die in the United States. Watnick, the nonprofit dialysis organization’s chief medical officer, immediately called Elizabeth McNamara, RN, vice president of patient care services and chief nursing officer. The patient had last undergone dialysis at one of Northwest Kidney Centers’ 19 sites a week earlier.